Teligent, Inc.
DelistedCIK 352998fmd_176ZJRN8194QWTW7GMXD2Z5GCQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2021, 46 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 9 | 18 | 34 | 44 | 218 | 216 | 158 | 156 | 45 |
| Cost of revenue | 6 | 6 | 12 | 17 | 23 | 28 | 33 | 43 | 42 | 49 |
| Net interest income | (0) | (1) | (0) | (1) | (13) | (13) | (11) | (12) | (21) | (29) |
| Gross profit | 2 | 3 | 6 | 17 | 21 | 35 | 27 | 22 | 24 | (4) |
| Research and development | 2 | 3 | 3 | 7 | 13 | 17 | 19 | 14 | 11 | 8 |
| Selling, general and administrative | 3 | 3 | 3 | 6 | 11 | 15 | 20 | 23 | 21 | 27 |
| Operating income | (3) | (3) | (0) | 4 | (3) | 3 | (12) | (15) | (8) | (140) |
| Interest expense | 0 | – | – | – | 0 | – | – | – | – | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Income before taxes | – | (4) | (0) | 5 | 7 | (12) | (15) | (36) | (25) | (120) |
| Income tax expense | (0) | (0) | (0) | 0 | 0 | 0 | (0) | (0) | 0 | 2 |
| Net income from continuing operations | (3) | (4) | (0) | 5 | 7 | (12) | (15) | (36) | (25) | (122) |
| Net income | (3) | (4) | (0) | 5 | 7 | (12) | (15) | (36) | (25) | (122) |
| Net income to common shareholders | – | (4) | (1) | 5 | 7 | (12) | (15) | (36) | (25) | (122) |